IDT Australia Limited (AU:IDT)
ASX:IDT
Want to see AU:IDT full AI Analyst Report?
IDT Stock Chart & Stats
AU$0.05
>-AU$0.01(-1.87%)
At close: 4:00 PM EST
AU$0.05
>-AU$0.01(-1.87%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.11
Previous CloseN/A
Volume22.00K
Average Volume (3M)336.94K
Market Cap
AU$13.98M
Enterprise ValueAU$22.47M
Total Cash (Recent Filing)AU$1.93M
Total Debt (Recent Filing)AU$9.86M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Aug 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding427,425,570
10 Day Avg. Volume373,970
30 Day Avg. Volume336,941
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)1.73
Price to Sales (P/S)1.92
P/FCF Ratio-5.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Business Model Resilience (CDMO Fee-for-service)IDT's fee-for-service CDMO model sells manufacturing and development as contracted services rather than relying on single-product sales. That structure yields diversified, client-funded revenue streams, reduces product development risk, and supports predictable contract revenues and long-term customer relationships.
Revenue Growth TrendConsistent, positive top-line growth (mid-single digits) indicates sustained customer demand for manufacturing services. Over 2–6 months this trend supports utilization and capacity planning, helping normalize fixed costs across more production volumes and underpinning longer-term revenue stability.
Asset Base / Equity StabilityA stable equity ratio and a tangible asset base in manufacturing provide operational resilience and collateral for financing. This supports continued contract fulfilment, potential incremental capex for capacity, and the ability to absorb demand fluctuations without immediate balance-sheet stress.
Bears Say
Negative Cash Flow GenerationPersistent negative operating and free cash flows reduce internal funding for working capital, maintenance and capacity investments. Over the medium term this elevates liquidity risk and increases reliance on external financing, which can constrain competitiveness and contract execution.
Ongoing Unprofitability / Margin PressureNegative EBIT and net margins signal structural cost or pricing pressures in manufacturing and development services. Sustained unprofitability erodes equity, limits reinvestment, and may necessitate pricing adjustments or cost restructuring to restore sustainable margins and long-term viability.
Rising Leverage And Negative ROEAn increasing debt-to-equity ratio combined with negative ROE reduces financial flexibility and raises interest burden risk. If earnings do not recover, higher leverage can constrain strategic investments, elevate refinancing risk, and limit the company's ability to compete or expand capacity.
IDT Australia Limited News
IDT FAQ
What was IDT Australia Limited’s price range in the past 12 months?
IDT Australia Limited lowest share price was AU$0.03 and its highest was AU$0.11 in the past 12 months.
What is IDT Australia Limited’s market cap?
IDT Australia Limited’s market cap is AU$13.98M.
When is IDT Australia Limited’s upcoming earnings report date?
IDT Australia Limited’s upcoming earnings report date is Aug 25, 2026 which is in 65 days.
How were IDT Australia Limited’s earnings last quarter?
IDT Australia Limited released its earnings results on Feb 17, 2026. The company reported -AU$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.003.
Is IDT Australia Limited overvalued?
According to Wall Street analysts IDT Australia Limited’s price is currently Overvalued.
Does IDT Australia Limited pay dividends?
IDT Australia Limited pays a Semiannually dividend of AU$0.008 which represents an annual dividend yield of N/A. See more information on IDT Australia Limited dividends here
What is IDT Australia Limited’s EPS estimate?
IDT Australia Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IDT Australia Limited have?
IDT Australia Limited has 427,425,570 shares outstanding.
What happened to IDT Australia Limited’s price movement after its last earnings report?
IDT Australia Limited reported an EPS of -AU$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 25.581%.
Which hedge fund is a major shareholder of IDT Australia Limited?
Currently, no hedge funds are holding shares in AU:IDT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
IDT Australia Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:IDT Sentiment 75%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$34.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.80%
12-Months-Change
Fundamentals
Return on Equity
-29.05%
Trailing 12-Months
Asset Growth
-8.11%
Trailing 12-Months
Company Description
IDT Australia Limited
IDT Australia Limited is an enterprise deeply involved in the entire lifecycle of pharmaceutical products, from initial research and development through to manufacturing and global distribution of both active pharmaceutical ingredients (APIs) and finished dosage forms. The company furnishes comprehensive analytical support, including the establishment of testing methodologies, stability assessments utilizing specialized chambers, and quality control laboratory services for both chemical and microbiological applications. Furthermore, its service offerings span project management, chemical processing, advanced analytical chemistry, pharmacy support, clinical trial packaging, and regulatory compliance assistance, alongside pharmaceutical development expertise across diverse dosage forms. Notably, IDT Australia also provides medicinal cannabis products and a broad array of contract manufacturing solutions. Established in 1975, the firm is headquartered in Boronia, Australia.
Technical Analysis
―
Little Green Pharma Ltd.
―
Medical Developments International Limited
―
―
Cronos Australia Ltd.
―
Options Prices
Currently, No data available
---